22 studies found for:    "methodist hospital" | Open Studies | "Lymphatic Diseases" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Administration of Donor MultiTAA-Specific T Cells for ALL
Condition: Leukemia, Lymphoblastic (Acute)
Intervention: Biological: MultiTAA-specific T cells
2 Recruiting Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Conditions: Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
Interventions: Biological: MABEL CTLs;   Drug: Cyclophosphamide;   Drug: Fludarabine
3 Recruiting Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Conditions: Non-Hodgkin's Lymphoma;   B-Cell ALL;   B-Cell CLL
Interventions: Genetic: CD19.CAR-CD28Z T Cells - dose escalation 2;   Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1
4 Recruiting Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
Intervention: Biological: CD19 Specific CAR T Cells
5 Recruiting Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Conditions: Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Lymphoproliferative Disease;   Lymphoma
Interventions: Biological: LMP, BARF1 & EBNA1 specific CTLs: A;   Biological: LMP, BARF1 & EBNA1 specific CTLs : B
6 Recruiting Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Biological: Antigen-Escalation Stage;   Biological: Dose-Escalation Study of T Cells
7 Recruiting Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Conditions: Lymphoma;   Myeloma;   Leukemia
Intervention: Biological: Kappa CD28 T cells
8 Recruiting T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Conditions: Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
Interventions: Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
9 Not yet recruiting Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Conditions: CD30-positive Lymphoma;   CD30-positive Solid Tumor
Interventions: Drug: Brentuximab Vedotin;   Drug: Alsertib
10 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib
11 Recruiting Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
Condition: Acute Lymphoid Leukemia
Interventions: Drug: Entospletinib;   Drug: VCR;   Drug: Dexamethasone;   Drug: CNS Prophylaxis
12 Recruiting Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Conditions: Adult B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Stage I B Lymphoblastic Lymphoma;   Stage II B Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
13 Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
14 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
15 Recruiting Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Conditions: Acute Undifferentiated Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies;   Childhood Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hairy Cell Leukemia;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Neoplasm of Uncertain Malignant Potential;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
16 Recruiting A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)
Conditions: Refractory Diffuse Large B Cell Lymphoma;   Refractory Primary Mediastinal B Cell Lymphoma;   Refractory Transformed Follicular Lymphoma
Intervention: Biological: KTE-C19
17 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
18 Recruiting Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Refractory Childhood Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis
19 Recruiting Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Lymphedema;   Sexual Dysfunction and Infertility;   Stage IA1 Cervical Cancer;   Stage IA2 Cervical Cancer;   Stage IB1 Cervical Cancer
Interventions: Procedure: Conization;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Therapeutic Conventional Surgery;   Procedure: Therapeutic Lymphadenectomy
20 Recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years